1.71
Schlusskurs vom Vortag:
$1.83
Offen:
$1.85
24-Stunden-Volumen:
167.64K
Relative Volume:
0.27
Marktkapitalisierung:
$134.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-9.52%
1M Leistung:
-8.56%
6M Leistung:
+176.21%
1J Leistung:
+76.29%
Citius Oncology Inc Stock (CTOR) Company Profile
Firmenname
Citius Oncology Inc
Sektor
Telefon
(908) 967-6677
Adresse
11 COMMERCE DRIVE, CRANFORD
Vergleichen Sie CTOR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CTOR
Citius Oncology Inc
|
1.71 | 152.83M | 0 | 0 | 0 | 0.00 |
![]()
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-23 | Hochstufung | Maxim Group | Hold → Buy |
2024-11-27 | Eingeleitet | Maxim Group | Buy |
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Is Citius Oncology Inc. a candidate for recovery playStock Surge & Safe Swing Trade Setup Alerts - newser.com
Sector ETF performance correlation with Citius Oncology Inc.July 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
Is Citius Oncology Inc. stock bottoming outOil Prices & Target Return Focused Stock Picks - newser.com
Heatmap analysis for Citius Oncology Inc. and competitorsMarket Sentiment Summary & Precise Swing Trade Alerts - newser.com
Why Citius Oncology Inc. stock is recommended by analystsJuly 2025 Summary & Verified Technical Signals - newser.com
Citius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How Citius Oncology Inc. stock benefits from tech adoptionWeekly Stock Summary & Long-Term Growth Stock Strategies - newser.com
How Citius Oncology Inc. stock performs in stagflationTrade Risk Summary & Low Drawdown Trading Strategies - newser.com
What to do if you’re stuck in Citius Oncology Inc.2025 Support & Resistance & Weekly Momentum Picks - newser.com
Will a bounce in Citius Oncology Inc. offer an exitMarket Movement Recap & Safe Entry Zone Identification - newser.com
Has Citius Oncology Inc. formed a bullish divergenceVolume Spike & Daily Volume Surge Signals - newser.com
Is it time to cut losses on Citius Oncology Inc.Trade Volume Report & Real-Time Stock Price Movement Reports - newser.com
Citius in talks over Lymphir access in global markets - The Pharma Letter
Citius Sets Up Access to Lymphir in Southern Europe - MarketScreener
Citius Oncology expands LYMPHIR access through named patient programs - Investing.com
Citius Oncology enters exclusive distribution agreement with Integris Pharma S.A. - MarketScreener
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Decline in Short Interest - Defense World
Is a relief rally coming for Citius Oncology Inc. holdersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
Is it too late to sell Citius Oncology Inc.July 2025 Final Week & High Yield Stock Recommendations - newser.com
Can volume confirm reversal in Citius Oncology Inc.July 2025 Highlights & Low Risk Entry Point Tips - newser.com
Using data tools to time your Citius Oncology Inc. exit2025 Earnings Impact & Technical Analysis for Trade Confirmation - newser.com
What MACD and RSI say about Citius Oncology Inc.Trade Risk Report & Long-Term Safe Return Strategies - newser.com
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in September - MarketBeat
Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World
Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - Nasdaq
Finanzdaten der Citius Oncology Inc-Aktie (CTOR)
Es liegen keine Finanzdaten für Citius Oncology Inc (CTOR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):